Novavax Inc. [NASDAQ: NVAX] closed the trading session at $18.62 on 10/18/22. The day’s price range saw the stock hit a low of $18.44, while the highest price level was $21.18. The company report on October 13, 2022 that Novavax COVID-19-Influenza Combination Vaccine Candidate Induced Antibody and T-Cell Responses Against SARS-CoV-2 and Homologous and Heterologous Influenza Strains.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Trial is the first of its kind to evaluate a combined COVID-19 and influenza vaccine.
Dose insights from Phase 1/2 trial will inform Phase 2 confirmation trial to begin in late 2022.
The stocks have a year to date performance of -86.99 percent and weekly performance of -1.85 percent. The stock has been moved at -66.24 percent over the last six months. The stock has performed -34.51 percent around the most recent 30 days and changed -68.74 percent over the most recent 3-months.
If compared to the average trading volume of 5.52M shares, NVAX reached to a volume of 5134984 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Novavax Inc. [NVAX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NVAX shares is $81.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NVAX stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JP Morgan have made an estimate for Novavax Inc. shares, keeping their opinion on the stock as Underweight, with their previous recommendation back on September 22, 2022. While these analysts kept the previous recommendation, BofA Securities raised their target price to Underperform. The new note on the price target was released on May 20, 2022, representing the official price target for Novavax Inc. stock. Previously, the target price had yet another drop from $315 to $265, while B. Riley Securities kept a Buy rating on NVAX stock.
The Average True Range (ATR) for Novavax Inc. is set at 2.35, with the Price to Sales ratio for NVAX stock in the period of the last 12 months amounting to 1.22.
NVAX stock trade performance evaluation
Novavax Inc. [NVAX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.85. With this latest performance, NVAX shares dropped by -34.51% in over the last four-week period, additionally sinking by -66.24% over the last 6 months – not to mention a drop of -88.50% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NVAX stock in for the last two-week period is set at 37.13, with the RSI for the last a single of trading hit 39.99, and the three-weeks RSI is set at 36.33 for Novavax Inc. [NVAX]. The present Moving Average for the last 50 days of trading for this stock 28.77, while it was recorded at 20.03 for the last single week of trading, and 59.16 for the last 200 days.
Novavax Inc. [NVAX]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Novavax Inc. [NVAX] shares currently have an operating margin of -147.13 and a Gross Margin at +98.90. Novavax Inc.’s Net Margin is presently recorded at -152.12.
Return on Equity for this stock declined to -1,265.72, with Return on Assets sitting at -83.85.
Novavax Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.90 and a Current Ratio set at 1.00.
Earnings per share (EPS) analysis for Novavax Inc. [NVAX] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NVAX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Novavax Inc. go to 0.00%.
Novavax Inc. [NVAX]: Insider Ownership positions
There are presently around $630 million, or 44.60% of NVAX stock, in the hands of institutional investors. The top three institutional holders of NVAX stocks are: VANGUARD GROUP INC with ownership of 7,350,925, which is approximately 5.511% of the company’s market cap and around 0.30% of the total institutional ownership; BLACKROCK INC., holding 4,258,441 shares of the stock with an approximate value of $79.29 million in NVAX stocks shares; and STATE STREET CORP, currently with $55.24 million in NVAX stock with ownership of nearly 18.887% of the company’s market capitalization.
Positions in Novavax Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 146 institutional holders increased their position in Novavax Inc. [NASDAQ:NVAX] by around 6,876,231 shares. Additionally, 207 investors decreased positions by around 6,500,586 shares, while 69 investors held positions by with 20,474,082 shares. The mentioned changes placed institutional holdings at 33,850,899 shares, according to the latest SEC report filing. NVAX stock had 53 new institutional investments in for a total of 1,237,054 shares, while 104 institutional investors sold positions of 2,445,503 shares during the same period.